PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30565854-0	2019	Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial.	Rosuvastatin Calcium	0-12	coagulation factor II, thrombin	Homo sapiens	25-33	
30565854-3	2019	Endogenous thrombin potential and peak were decreased by 10% and 5% with rosuvastatin therapy.	Rosuvastatin Calcium	73-85	coagulation factor II, thrombin	Homo sapiens	11-19	
30565854-11	2019	Endogenous thrombin potential (ETP) increased from baseline to end of study in non-statin users (mean 97.22 nm*min; 95% CI, 40.92-153.53) and decreased in rosuvastatin users (mean -24.94 nm*min; 95% CI, -71.81 to 21.93).	Rosuvastatin Calcium	155-167	coagulation factor II, thrombin	Homo sapiens	11-19	
30565854-13	2019	The thrombin peak increased in both non-statin (mean 20.69 nm; 95% CI, 9.80-31.58) and rosuvastatin users (mean 8.41 nm; 95% CI -0.86 to 17.69).	Rosuvastatin Calcium	87-99	coagulation factor II, thrombin	Homo sapiens	4-12	
30565854-17	2019	We conclude that rosuvastatin reduces thrombin generation potential in patients who had VTE.	Rosuvastatin Calcium	17-29	coagulation factor II, thrombin	Homo sapiens	38-46